Michael S. Sitrick

Abraxis BioScience, Inc. manufactures specialty pharmaceutical products. The company develops, manufactures and markets injectable products and leverages revolutionary technology such as its nab(TM) platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life threatening diseases. The company is located in Schaumburg, IL

Part of Resources Connection, Inc., Sitrick & Co. is a strategic communications firm that specializes in corporate, financial, transactional, reputation, and crisis communications, as well as crisis management. The company is based in Los Angeles, CA. The company has an extensive and successful practice in each of these areas, providing counsel and services to help launch companies, support or defend against litigation, combat short-sellers, deal with data breaches, and other events that could affect its clients' business value, market value, and overall reputation. The company was founded by Michael S. Sitrick. Sitrick was acquired by Resources Connection, Inc. on November 23, 2009.

APP Pharmaceuticals, Inc. develops, manufactures and markets injectable pharmaceutical products with a primary focus on the oncology, anti-infective, anesthetic/analgesic and critical care markets. It offers one of the most comprehensive product portfolios used in hospitals, long-term care facilities, alternate care sites and clinics within North America and manufactures a comprehensive range of dosage formulations. The company is headquartered in Los Angeles, CA.

Part of Triangle Industries, Inc., National Can Corp. is an American company that manufactures food and nonfood containers.

The Jewish Federation Council of Los Angeles provides emergency relief and social services. It identifies and funds social service, humanitarian needs in Israel and around the world. It helps to alleviate Jewish poverty, provide emergency relief, and support the Los Angeles community. The organization is headquartered in Los Angeles, CA

Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA.